US Pharm.
2008;33(1):14.
Pharmacists field questions
about such self-care topics as motion sickness on a daily basis. While motion
sickness is usually a relatively trivial complaint, it can interfere with the
sufferer's work and hamper the enjoyment normally found in hobbies, vacations,
and travel.
Prevalence of Motion
Sickness
Virtually all
persons with fully intact physiological systems for detection of motion can be
made motion sick, given the correct type of stimulus.1 The
prevalence of motion sickness varies with the type of stimulus and the
specific group of patients, but is almost 60% in children traveling in cars or
planes, and as high as 100% of those in boats in rough weather.2
The prevalence is lower in seasoned travelers.
Etiology of Motion Sickness
Humans detect
motion through three sources of input to the nervous system.3 One
is the vestibular system. Movement is detected in this system by stimulation
of hair cells in the semicircular canals and in the maculae of the utricle and
sacculus. Movement is registered in all three dimensions when endolymph moves
through the semicircular canals or when small particles known as otoliths
impact on hair cells.3,4 Through these mechanisms, the vestibular
system facilitates spatial orientation, maintains balance, and helps stabilize
vision.1
Another source of motion
detection is visual. When the body moves, the eyes usually detect that motion.
They measure the type of motion and its direction, rate, and force. When the
motion ceases, the patient uses visual input to confirm that the body is
still.
The final source of motion
perception is the proprioceptive system.3 This system consists of
the muscles, ligaments, and tendons that the body uses to detect motion. They
are critical in such activities as allowing the person to stand erect with the
eyes closed. In this position, the person is able to remain erect by sensing
and responding to the various movements of the legs.
Normally, the three sources of
detecting motion are in agreement with one another. For instance, the driver
of a car registers input from the proprioceptive system as he feels the motion
on the legs, arms, and posterior when the car endures the uneven roughness and
curves of the road. In a similar manner, the vestibular system also registers
movement of the car, whether it is in forward or reverse, when it is turning,
and even when it rocks from side to side. The visual system comes into play
since the driver must constantly look outward to drive safely and anticipate
road hazards. Thus, for the driver, the three sources of motion detection are
in full agreement. There is no question that the car is moving, and there is
little risk of motion sickness.
Motion sickness may occur when
one of the sources of motion detection does not agree with the other two. In
the majority of cases, visual input does not coincide with
vestibular/proprioceptive input. The theory that encompasses and explains
these concepts are known as the "neural mismatch" or "sensory conflict"
theory.
Two Types of Motion
Sickness
There are two types
of motion sickness. The first and most common occurs when the eyes do not
register motion but the vestibular/proprioceptive systems do. This type can
occur on land (caused by automobiles, trains, and theme park rides); on the
sea as seasickness or "mal de mer" (caused by boats, standard or hydrofoil
ferries, and survival rafts); in the air as airsickness (caused by gliders,
hovercraft, helicopters, and planes of all descriptions); and in space as
spacesickness (e.g., riding the Space Shuttle).1,3 For example, the
head of a small child in the backseat of a car is often below the level of the
windows, rendering him unable to see out to observe the rapidly passing
landscape. Passengers may also be absorbed in reading or playing computer
games. In these cases, the eyes do not register the various movements of the
car, leaving the patient bereft of the input needed to prevent a sensory
conflict.
The second type of motion
sickness is sometimes referred to as "reverse motion sickness," as it is the
opposite of the traditional type. In this case, the eyes register motion, but
the vestibular/proprioceptive systems do not agree with the visual input. The
sources of confusing "optokinetic" visual input include using
microfiche/microfilm machines; attending wide-screen movie theaters (e.g., the
1950/1960s triple-screen "Cinerama" movies, the more modern IMAX theaters);
watching movies with jerky and unpredictable camera movements (e.g., "The
Blair Witch Project"); playing video games (e.g., PlayStation, Xbox); trying
to read a moving map navigation system while driving; and using driving
simulators, fixed-base flight simulators, and head-mounted and fixed-base
virtual reality equipment.1,4,5 In all of these cases, body motion
does not exist as the eyes see it. People may attempt to compensate for the
illusion of movement by unconsciously moving their bodies in a postural
swaying motion in the direction of the implied movement.1,5
Epidemiology of Motion
Sickness
The hypothesized
etiology of motion sickness explains why patients with a bilateral loss of the
vestibular system are seemingly immune to the condition in normal
circumstances.1 On the other hand, patients with vertigo, Meniere's
disease, or migraine are more prone to motion sickness. Gender and age also
predict motion sickness. Females are more susceptible, in a 5:3 male to female
ratio; females also experience higher rates of nausea and vomiting.1,6
Age and motion sickness are
associated in a bimodal fashion. For instance, infants and extremely young
children do not experience symptoms of motion sickness. The age of onset for
the condition is usually ages 6 to 7, and the greatest incidence is in those 9
to 10 years of age. Following that peak, susceptibility decreases, probably
due to the phenomenon of habituation or adaptation.1,2,6
Studies demonstrate that the
person in control of a vehicle is less prone to become motion sick. Thus, the
driver or pilot is protected, while the passengers are at higher risk.1
The reason is simple. The pilot of a watercraft is able to see and anticipate
rougher water and the subsequent movements of the ship. On the other hand, the
passenger is jerked and thrown about seemingly at random. Young children in
car seats that restrict them to a location where they cannot observe the
outside scenery are particularly vulnerable.
Manifestations of Motion
Sickness
The most well-known
outcome of motion sickness is vomiting, preceded by nausea.2
However, sufferers also experience such manifestations as malaise, pallor,
yawning, restlessness, warmth, drowsiness, belching, sialorrhea, headache, and
sweating.2 Patients may feel relief after a single bout of
vomiting, but in a few cases, the vomiting can be protracted and severe.
Adaptation to Motion
The epidemiology of
motion sickness in automobiles clearly demonstrates that older children do not
experience it as much as younger children. Further, those taking a second or
third cruise experience it less than first-time travelers. Patients who have
been exposed to a provocative motion are thought to adapt to that motion,
lessening the risk of motion sickness upon future exposures to the same type
of motion.1 The duration of the adaptation is individual. Patients
who wait to take a second cruise until many years after the initial venture
may experience motion sickness again
Treatment of Motion
Sickness
Nonprescription
products for motion sickness are useful for preventing the problem when taken
prior to travel, and also in treating the illness once it has begun to
manifest. Antihistamines are the only FDA-approved nonprescription
intervention. Three antihistamines are available, differing in the ages for
which they may be recommended and their durations of action.2
Meclizine (e.g., Bonine and Dramamine Less Drowsy Formulas, both available as
25-mg tablets) is useful in a dose of 25 to 50 mg once daily for patients 12
and older.5 There is no safe meclizine dose for those under 12
years. Cyclizine (e.g., Marezine, Bonine for Kids) is given in doses of 50 mg
every 4 to 6 hours to those aged 12 and older, with a daily maximum of 200 mg,
and in doses of 25 mg every 6 to 8 hours for those aged 6 through 11 years of
age, with a daily maximum of 75 mg. There is no safe cyclizine dose under 6
years of age. Dimenhydrinate (e.g., Dramamine Original Formula 50-mg tablets)
is given in a dose of 50 to 100 mg every 4 to 6 hours to those 12 and older,
with a daily maximum of 400 mg; the dose is 25 to 50 mg every 6 to 8 hours in
those age 6 though 11, with a daily maximum of 150 mg; the dose is 12.5 to 25
mg in those age 2 through 5, with a daily maximum of 75 mg. There is no safe
dimenhydrinate dose for those younger than 2 years. A liquid form of Dramamine
was discontinued several years ago.
All antihistamines carry
contraindications against use with emphysema, chronic bronchitis, glaucoma, or
difficulty in urinating due to enlargement of the prostate gland, unless a
physician is consulted. Meclizine and cyclizine cause drowsiness, and
dimenhydrinate causes marked drowsiness.2 For this reason, they
must also be used with caution in patients who drive or operate heavy
machinery. They should also be avoided in those taking sedatives or
tranquilizers and those who use alcohol.
Various products sold for
motion sickness and nausea lack the FDA-approved efficacy that would be needed
for a confident recommendation. They include ginger, acupressure bands, and
such unproven homeopathic remedies as silver nitrate, borax, nux vomica,
poison ivy, petroleum, and tobacco.7,
Prevention of Motion
Sickness
Patients flying in
fixed-wing aircraft should choose seats over the wings, as the plane's center
of gravity is less susceptible to motion, minimizing in-flight vibratory
oscillation.9 Passengers in automobiles should strive not to read,
watch television, work with laptop computers, or play computer games. Rather,
they should look outside of the car
Mal de Debarquement
The pharmacist may
also be asked about a condition related to motion sickness known as "mal de
debarquement."1,10,11 These patients have usually been on a
flight or cruise without incident, but upon disembarking, they feel unsteady,
and the floor seems to tilt or rock. The trip may have been no longer than a
3-hour dinner cruise. In the more severe cases, the patient may experience
full-blown motion sickness. Standard motion sickness medications seldom give
relief, but the condition resolves in a few hours or days in
most cases
REFERENCES
1. Golding JF. Motion sickness susceptibility. Auton Neurosci. 2006;129:67-76.
2. Pray WS. Nonprescription Product Therapeutics. 2nd ed. Baltimore, MD: Lippincott Williams & Wilkins; 2005.
3. Zajonc TP, Roland PS. Vertigo and motion sickness. Part I: vestibular anatomy and physiology. Ear Nose Throat J. 2005;84:581-584.
4. Muth ER, Walker AD, Fiorello M. Effects of uncoupled motion on performance. Hum Factors. 2006;48:600-607.
5. Merhi O, Faugliore E, Flanagan M, et al. Motion sickness, console video games, and head-mounted displays. Hum Factors. 2007;49:920-934.
6. Flanagan MB, May JG, Dobie TG. Sex differences in tolerance to visually-induced motion sickness. Aviat Space Environ Med. 2005;76:642-646.
7. Wong C. How to make a homeopathic
travel kit for motion sickness and nausea. Available at: www.altmedicine.
about.com/cs/homeopathy/a/Travel
Nausea.htm. Accessed
November 29, 2007.
8. White B. Ginger: an overview. Am Fam Physician. 2007;75:1689-1691.
9. Hinninghofen H, Enck P. Passenger well-being in airplanes. Auton Neurosci. 2006;129:80-85.
10. Lewis RF. Frequency-specific mal de debarquement. Neurology. 2004;63:1241.
11. DeFlorio PT, Silbergleit R. Mal de debarquement presenting in the emergency department. J Emerg Med. 2006;31:377-379.
12. Spinks AB, Wasiak J, Villanueva
EV, Bernath V. Scopolamine (hyoscine) for preventing and treating motion
sickness. Cochrane Database Syst Rev. 2007;3:CD002851.
†To comment on this article,
contact
editor@uspharmacist.com.
Correction: In the November 2007 issue, it was reported that the monoamine oxidase inhibitor Marplan (isocarboxazid) is no longer marketed, when in fact Marplan is currently marketed in the U.S. by Validus Pharmaceuticals, Inc.